Chronotherapeutics: The Relevance of Timing in Cancer Therapy
- 449 Downloads
Cell physiology is regulated along the 24-h time scale by a circadian timing system composed of molecular clocks within each cell and a central coordination system in the brain. The mammalian molecular clock is made of interconnected molecular loops involving at least 12 circadian genes. The cellular clocks are coordinated by the suprachiasmatic nuclei, a hypothalamic pacemaker which also helps the organism adjust to environmental cycles. The rest–activity rhythm is a reliable marker of the circadian system function in both rodents and man. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also in tumor promotion or growth.
Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest–activity cycle. The clinical relevance of the chronotherapy principle, i.e. treatment administration as a function of rhythms, has been demonstrated in randomized multicenter trials.
Chronotherapeutic schedules have been used to safely document the activity of the association of oxaliplatin, 5-FU and leucovorin against metastatic colorectal cancer and to set up a new medicosurgical management of this disease which achieved unprecedented long term survival.
The chronotherapy concept offers further promises for improving current cancer treatment options as well as for optimizing the development of new anticancer or supportive agents
KeywordsCircadian Rhythms Chronopharmacology Chronotherapy Quality of life Survival
- 6.Klein DC, Moore RY, Reppert SM (1991) Suprachiasmatic Nucleus, the Mind’s Clock. Oxford University Press, Oxford, 467 ppGoogle Scholar
- 7.Rosenwasser AM, Wirz-Justice A (1997) Circadian rhythms and depression: clinical and experimental models. In: Redfern P, Lemmer B (eds) Physiology and Pharmacology of Biological Rhythms. Springer-Verlag, Berlin, pp 457–485Google Scholar
- 15.Hofsethh LJ, Hussain SP, Harris CC (2004) P53/ 25 years after its discovery. Trends Pharmacol Sci 25:177–181Google Scholar
- 16.Kellog DR (2003) Wee1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci 116:4883–4890Google Scholar
- 19.Lévi F (1997) Chronopharmacology of anticancer agents. In: Redfern P, Lemmer B (eds) Physiology and Pharmacology of Biological Rhythms. Springer-Verlag, Berlin, pp. 299–331Google Scholar
- 22.Lévi F (2003) Circadian rhythms in 5-fluorouracil pharmacology and therapeutic applications. In: Rustum Y (ed) Fluoropyrimidines in Cancer Therapy. The Humana Press Inc, New Jersey, USA, pp 107–128Google Scholar
- 27.Squalli A, Oustrin J, Houin G, etal. (1989) Clinical chronopharmacokinetics of doxorubicin (DXR). Ann Rev Chronopharmacol 5:393–396Google Scholar
- 28.Harris B, Song R, Soong S, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197–201PubMedGoogle Scholar
- 31.Bjarnason GA, Jordan R (2000) Circadian variation of cell proliferation and cell protein expression in man : clinical implications. In: Meijer L, Jézéquel A, Ducommun B (eds) Progress in Cell Cycle Research. vol 4. Kluwer Academic, New York, pp 193–206Google Scholar
- 35.Schmiegelow K, Glomstein A, Kristinsson J, Salmi T, Schroder H, Bjork O (1997) Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 19(2):102–109CrossRefPubMedGoogle Scholar
- 41.Lévi F, Zidani R, Vannetzel JM, etal. (1994) Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst 86:1608–1617PubMedGoogle Scholar
- 42.Lévi F, Zidani R, Misset JL for the International Organization for Cancer Chronotherapy (1997) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681–686Google Scholar
- 44.Giacchetti S, Bjarnason G, Garufi C, etal. (2004) First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer:4-day chronomodulated (FFL4–10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). Proc Am Soc Clin Oncol 23:731Google Scholar
- 53.Garufi C, Bjarnason G, Giacchetti S, etal. on behalf of the EORTC Chronotherapy Group (2005) Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963. Proc Am Soc Clin Oncol, 124:abstr 3553Google Scholar
- 54.Innominato PF, Focan C, Bjarnason GA, etal. on behalf of the EORTC Chronotherapy Group (2005) Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: an international multicenter study (EORTC 05963). Proc Am Soc Clin Oncol 24:abstr 8029 Google Scholar